compared the total pneumococcal IgG antibody, IgG subclass antibody titers, and serotype-specific antibody concentrations (4, 6B, 9V, 14, 18C, 19F, 23F, 1, and 5) in children who had received 2 doses Prevnar followed by a dose of
Pneumovax to evaluate the most useful assays in clinical practice (25).
After vaccination with
Pneumovax, 7 children with recurrent respiratory infections (19%) had a defective antibody response to at least 4 of the 6 serotypes tested (3, 4, 6B, 9N, 18C, and 19F).
PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.
Pfizer vaccines (formerly Wyeth) are also expanding PCV13 indications into older age groups especially those with underlying co-morbidities who are currently vaccinated with 23-valent
Pneumovax (PPSV).
The percentage of enrollees who received
Pneumovax rose from 44% to 99%.
Another vaccine,
Pneumovax 23, is also FDA-approved for people as young as 50, but ACIP guidance currently restricts it to children and people over 65, unless they are in a high-risk category, so Prevnar13 will cover the more than 42 million people between 50 and 65 the current drug misses, as well as the more than 72 million people 65 and older, and children.
Pneumovax did not worsen disease activity in patients with rheumatoid arthritis and systemic lupus erythematosus, but a substantial number of them had a poor response to the vaccine.
Another vaccine,
Pneumovax 23, is FDA-approved only for children and people over 65, unless they are in a high-risk category, so Prevnar13 will cover the more than 42 million people between 50 and 65 the current drug misses, as well as the more than 72 million people 65 and older, and children.
Minor wounds, abrasions and joint sprains are treated, and common vaccinations such as influenza, tetanus,
pneumovax, and Hepatitis A & B are available at most locations.
The launch of Pfizers Prevnar 13 for adults is anticipated in 2011 and the vaccine is expected to quickly replace
Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.
Datamonitor anticipates the launch of Pfizers Prevnar 13 for adults in 2011 and expects the vaccine to quickly replace Merck & Co's
Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.
Minor wounds, abrasions and joint sprains are also treated, and common vaccinations such as influenza, tetanus,
pneumovax, and Hepatitis A & B and meningitis are available at most locations.
)